This company has been marked as potentially delisted and may not be actively trading. AzurRx BioPharma (AZRX) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock AZRX vs. NLTX, CYBN, VIRI, WHWK, LITS, OSTX, ELYM, ATNM, AADI, and NBRVShould you be buying AzurRx BioPharma stock or one of its competitors? The main competitors of AzurRx BioPharma include Neoleukin Therapeutics (NLTX), Cybin (CYBN), Virios Therapeutics (VIRI), Whitehawk Therapeutics (WHWK), Lite Strategy (LITS), OS Therapies (OSTX), Eliem Therapeutics (ELYM), Actinium Pharmaceuticals (ATNM), Aadi Bioscience (AADI), and Nabriva Therapeutics (NBRV). AzurRx BioPharma vs. Its Competitors Neoleukin Therapeutics Cybin Virios Therapeutics Whitehawk Therapeutics Lite Strategy OS Therapies Eliem Therapeutics Actinium Pharmaceuticals Aadi Bioscience Nabriva Therapeutics Neoleukin Therapeutics (NASDAQ:NLTX) and AzurRx BioPharma (NASDAQ:AZRX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations. Which has better valuation and earnings, NLTX or AZRX? Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than AzurRx BioPharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeoleukin TherapeuticsN/AN/A-$57.56M-$3.11-7.55AzurRx BioPharmaN/AN/A-$32.67M-$11.50-0.41 Which has more volatility & risk, NLTX or AZRX? Neoleukin Therapeutics has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Comparatively, AzurRx BioPharma has a beta of 1.51, indicating that its stock price is 51% more volatile than the S&P 500. Is NLTX or AZRX more profitable? Neoleukin Therapeutics' return on equity of -37.22% beat AzurRx BioPharma's return on equity.Company Net Margins Return on Equity Return on Assets Neoleukin TherapeuticsN/A -37.22% -30.91% AzurRx BioPharma N/A -482.96%-258.47% Does the media refer more to NLTX or AZRX? In the previous week, Neoleukin Therapeutics' average media sentiment score of 0.00 equaled AzurRx BioPharma'saverage media sentiment score. Company Overall Sentiment Neoleukin Therapeutics Neutral AzurRx BioPharma Neutral Do institutionals & insiders believe in NLTX or AZRX? 52.4% of Neoleukin Therapeutics shares are owned by institutional investors. Comparatively, 6.3% of AzurRx BioPharma shares are owned by institutional investors. 1.6% of Neoleukin Therapeutics shares are owned by company insiders. Comparatively, 7.3% of AzurRx BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. SummaryNeoleukin Therapeutics and AzurRx BioPharma tied by winning 4 of the 8 factors compared between the two stocks. Get AzurRx BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AZRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AZRX vs. The Competition Export to ExcelMetricAzurRx BioPharmaPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$43.46M$1.03B$6.14B$10.64BDividend YieldN/A4.84%5.66%4.69%P/E Ratio-0.431.2585.7227.64Price / SalesN/A30.85631.45142.60Price / CashN/A17.6438.3262.20Price / Book-6.137.3613.096.79Net Income-$32.67M-$7.96M$3.30B$275.88M AzurRx BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AZRXAzurRx BioPharmaN/A$4.66+16.5%N/A+854.7%$43.46MN/A-0.4312NLTXNeoleukin TherapeuticsN/A$17.71-0.6%N/A-52.6%$166.44MN/A-5.6990High Trading VolumeCYBNCybinN/A$6.02+2.3%$85.00+1,311.0%N/A$152.11MN/A-1.3850High Trading VolumeVIRIVirios TherapeuticsN/A$7.70-2.7%$5.00-35.1%+125.4%$148.29MN/A-28.525Gap UpWHWKWhitehawk Therapeutics0.6683 of 5 stars$1.94+2.1%N/AN/A$91.43M$25.98M-32.3321News CoverageAnalyst UpgradeLITSLite StrategyN/A$2.55+5.4%N/AN/A$90.91M$65.30M-0.54100News CoverageAnalyst ForecastOSTXOS TherapiesN/A$1.97+0.5%$18.00+813.7%N/A$62.34MN/A-2.49N/AELYMEliem TherapeuticsN/A$1.99-6.6%N/A-65.6%$59.21MN/A-3.759ATNMActinium Pharmaceuticals1.9109 of 5 stars$1.61+0.3%$4.50+180.4%-4.2%$50.07MN/A-1.1530AADIAadi BioscienceN/A$1.90-1.0%N/A+7.0%$46.92M$25.07M-0.8340NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070 Related Companies and Tools Related Companies NLTX Alternatives CYBN Alternatives VIRI Alternatives WHWK Alternatives LITS Alternatives OSTX Alternatives ELYM Alternatives ATNM Alternatives AADI Alternatives NBRV Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AZRX) was last updated on 10/10/2025 by MarketBeat.com Staff From Our Partners"I'm risking my reputation on this"The Fed rate cut truth they don't want you to know The Fed's 25 basis point cut isn't just monetary policy…...Crypto 101 Media | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredRobinhood warningA strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredTrump to get REVENGE on the banks??Rumors are swirling that Trump could target the banking system by upending the $5 trillion-a-day SWIFT network...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AzurRx BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AzurRx BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
